Aviceda Announces Successful Submission of an Investigational New Drug (IND) and Fast Track Designation (FTD) Application for AVD-104 for the Treatment of Geographic Atrophy

By /

Aviceda Therapeutics today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

Scroll to Top